Table 1. Timeline of patient investigations.

CT: Computed tomography; CTPA: Computed tomography pulmonary angiogram; DLC/O: Diffusing capacity for carbon monoxide; EDV: End-diastolic volume; EF: Ejection fraction; FEV: Forced expiratory volume; FVC: Forced vital capacity; KCO: Carbon monoxide transfer coefficient; LV: Left ventricle; MRI: Magnetic resonance imaging; PAA: Pulmonary artery aneurysm; PG: Pressure gradient; RSVP: Right ventricular systolic pressure; RV: Right ventricle; TR: Tricuspid Regurgitation

Dates	October 2019	November 2019	March 2020	September 2020	October 2020	November 2021	April 2022	January 2023
Investigation	CT angiography	Echocardiogram	Spirometry	Echocardiogram	CTPA	Cardiac MRI	Post-COVID cardiac MRI	Preoperative Cardiac catheterization
Findings	Main PAA measuring 5.5x4.7 cm; Centrilobular pulmonary emphysema	TR max PG= 43.4 mmHg; RSVP=48.4 mmHg; Diagnosis of pulmonary hypertension	FVC 110%; FEV 97%; FEV/FVC= 74%; DLCO 48% KCO 70%	Echo: RVSP 60mmHg	PAA size 5.4x4.9 cm	PAA size 5.8x5.1cm increase of 0.4mm in one year	Depressed LV contractility with index EDV= 117ml/m2 , EF=41% (previously EF=57%); Mildly depressed contractility of RV with index EDV= 74ml/m2, EF= 46% (previous reports EF was 52%)	Major coronaries are free of disease, and preserved LV systolic function; Severe mitral valve regurgitation and moderate aortic valve regurgitation; Severe dilatation of pulmonary artery trunk